Yes, yes and yes, but,
It takes money to play in the cancer space and there were positives in the reports.
MagSense® HER2 breast cancer study interim results released
MagSense® HER2 imaging agent passes stability milestone
Sponsored Research Agreement executed with researchers at Massachusetts General Hospital focuses on MRI
Research collaboration with University of Sydney expands brain cancer project
Move to new facility completed
The Company’s cash balance stood at $8.5 million at end of June 2022, down from $13.4 million at December 2021. Cash will be boosted in Q3 2022 by the expected receipt of $2.5 million in research & development tax incentives from the Australian Taxation Office in respect of its 2021 research & development costs.
In March 2022, the Company released findings from the first five patients in the MagSense® HER2 Breast Cancer Study. Those interim results noted that there had been no safety or tolerability issues reported related to the imaging agent and that there was evidence that the MagSense® imaging agent is successfully reaching the patient’s lymph nodes. To date, results from additional patients enrolled remain consistent with the previously reported findings.
Also during the first half of the year the Company, together with its collaborator Patrys Limited, entered into a research engagement with The University of Sydney related to the potential for the Company’s MagSense® technology to detect brain cancers leveraging the university’s expertise in models of Glioblastoma Multiforme, an aggressive and deadly form of brain cancer. The Company expects to report on the progress of these studies in 2023
News 
Market Data 
Discover 
